• In the study where it helped patients lose weight, the drug also raised good cholesterol, or high-density lipoprotein (HDL), by 23%, almost as much as Niaspan, the sustained-release niacin drug made by Kos Pharmaceuticals (nasdaq: KOSP - news - people ) that is the main currently available treatment for raising HDL. Rimonabont also cut triglycerides, another risk factor for heart disease, by 16%.

    FORBES: Lose Weight, Quit Smoking With One Pill

  • The case for raising HDL rests not on clinical trials but mostly on studies showing circumstantial connections.

    FORBES: Magazine Article

  • For Fogelman, who has been working HDL drugs for years and has several more in the Bruin pipeline, the promise is huge.

    FORBES: Novartis Enters 'Good Cholesterol' Battle

  • For niacin, used to raise HDL, and for fish oil pills its 10, 000.

    FORBES: Another Blow For Merck And Schering

  • Researchers who hope for a successful, HDL-raising drug now say they worry pharmaceutical companies may not revisit the approach.

    WSJ: New Rules for Boosting Good Cholesterol

  • Although niacin, a natural vitamin, has been used for decades to raise HDL, a clinical benefit has never been demonstrated.

    FORBES: HPS2-THRIVE: No Benefit, Signal Of Harm For Niacin Therapy

  • He points out that patients received the drug, a mutation of HDL cholesterol, for only five weeks.

    FORBES: Defending Esperion

  • Alan Tall of Columbia University says the results were "interesting and exciting, " and, moreover, were a "proof of concept" for the idea that raising HDL cholesterol can move plaque out of the arteries.

    FORBES: Magazine Article

  • Researchers speculating about what went wrong thought perhaps torcetrapib made HDL that didn't work, or that HDL itself (short for high-density lipoprotein, and often called "good cholesterol") was less powerful than they thought.

    FORBES

  • For some experimental medicines, like HDL-raising drugs being developed by Merck and Eli Lilly that are known as CETP inhibitors, this result only affects how much value investors assign to those research programs.

    FORBES: Why Merck's Niacin Failure Will Scare Drug Researchers

  • At a major cardiology meeting last November and this March, Merck distributed promotional materials emphasizing the importance of HDL to prime the market for the new drug.

    FORBES: Is Merck Flying Blind?

  • If that doesn't work--and it won't for many people--try an ancient HDL-raiser, the B vitamin niacin, if you can live with its annoying side effect (hot flashes).

    FORBES: Magazine Article

  • By using olive oil, you can decrease your total-cholesterol levels while maintaining your HDL levels, thus decreasing your risk for heart disease.

    CNN: What's your cholesterol IQ?

  • HPS2-THRIVE adds to the string of failures associated with trials of HDL-related therapies, although some hope remains for CETP inhibitors, despite the failure of two large clinical trials.

    FORBES: HPS2-THRIVE: No Benefit, Signal Of Harm For Niacin Therapy

  • Another Zetia benefit: In studies, some patients not only saw "bad" LDL cholesterol decrease, they also saw a slight increase in "good" HDL cholesterol, which is thought to be better for health.

    FORBES: Schering-Plough And Merck's New Hope

  • And researchers and Wall Street analysts have had another reason for viewing it as an also-ran: It is only half as effective as torcetrapib, boosting HDL by only 30%.

    FORBES: Pfizer's Next Problem

  • It represented a fast approach to entering the HDL market and an example of getting researchers in different disease disciplines to work together, a triumph for Kim as he tried to revitalize Merck's research efforts.

    FORBES: Merck's Good Cholesterol Battle

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定